{
    "eid": "2-s2.0-85165676961",
    "title": "Acute kidney injury in patients receiving immune checkpoint inhibitors: a retrospective real-world study",
    "cover-date": "2023-09-01",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Oncology",
            "@code": "2730",
            "@abbrev": "MEDI"
        },
        {
            "@_fa": "true",
            "$": "Cancer Research",
            "@code": "1306",
            "@abbrev": "BIOC"
        }
    ],
    "keywords": [
        "Acute kidney injury",
        "Cancer",
        "Chronic kidney disease",
        "Immune checkpoint inhibitors",
        "Immunotherapy",
        "Malignancy"
    ],
    "authors": [
        "Nuttha Lumlertgul",
        "Pietro Vassallo",
        "Florence Tydeman",
        "Natasha Lewis",
        "Abigail Hobill",
        "Kittisak Weerapolchai",
        "Nurul Zaynah Nordin",
        "Nina Seylanova",
        "Luke Martin",
        "Armando Cennamo",
        "Yanzhong Wang",
        "Anne Rigg",
        "Nisha Shaunak",
        "Marlies Ostermann"
    ],
    "citedby-count": 0,
    "ref-count": 29,
    "ref-list": [
        "Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer",
        "Improved survival with ipilimumab in patients with metastatic melanoma",
        "Immune checkpoint inhibitor nephrotoxicity: update 2020",
        "Immune-related adverse events associated with immune checkpoint blockade",
        "Programmed cell death protein 1 inhibitor treatment is associated with acute kidney injury and hypocalcemia: meta-analysis",
        "Clinical features and outcomes of immune checkpoint inhibitor-associated AKI: a multicenter study",
        "Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors",
        "The incidence, causes, and risk factors of acute kidney injury in patients receiving immune checkpoint inhibitors",
        "Long-term kidney function of patients discharged from hospital after an intensive care admission: observational cohort study",
        "Long-term outcomes in patients with acute kidney injury",
        "Acute kidney injury in patients with cancer",
        "Acute kidney injury as a risk factor for mortality in oncological patients receiving checkpoint inhibitors",
        "Acute kidney injury associated with immune checkpoint inhibitor therapy: incidence, risk factors and outcomes",
        "Acute kidney injury in patients treated with anti-programmed death receptor-1 for advanced melanoma: a real-life study in a single-centre cohort",
        "Incidence, predictors, and survival impact of acute kidney injury in patients with melanoma treated with immune checkpoint inhibitors: a 10-year single-institution analysis",
        "Mortality after acute kidney injury and acute interstitial nephritis in patients prescribed immune checkpoint inhibitor therapy",
        "KDIGO clinical practice guidelines for acute kidney injury",
        "Renal recovery after acute kidney injury",
        "KDOQI US commentary on the 2012 KDIGO clinical practice guideline for the evaluation and management of CKD",
        "New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)",
        "Acute kidney injury in patients treated with immune checkpoint inhibitors",
        "Renal adverse effects of immune checkpoints inhibitors in clinical practice: ImmuNoTox study",
        "Immune checkpoint inhibitor-associated acute kidney injury and mortality: an observational study",
        "Incidence and risk factors of acute kidney injury, and its effect on mortality among Japanese patients receiving immune check point inhibitors: a single-center observational study",
        "Acute kidney injury in advanced lung cancer patients treated with PD-1 inhibitors: a single center observational study",
        "Immune checkpoints inhibitors and its link to acute kidney injury and renal prognosis",
        "The role of kidney biopsy in immune checkpoint inhibitor-associated AKI",
        "Renal toxicities associated with pembrolizumab",
        "Is rechallenge appropriate in patients that develop immune checkpoint inhibitor-associated AKI?: PRO"
    ],
    "affiliation": [
        {
            "affiliation-city": "London",
            "@id": "60005518",
            "affilname": "Guy's and St Thomas' NHS Foundation Trust",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60005518",
            "affiliation-country": "United Kingdom"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60022183",
            "affilname": "King Chulalongkorn Memorial Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60022183",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "London",
            "@id": "60011520",
            "affilname": "King's College London",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60011520",
            "affiliation-country": "United Kingdom"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60002620",
            "affilname": "Faculty of Medicine, Chulalongkorn University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002620",
            "affiliation-country": "Thailand"
        }
    ],
    "funding": [
        "International Society of Nephrology",
        "Guy\u2019s & St Thomas\u2019 NHS Foundation Trust"
    ]
}